AsiaPharm Of China, GlycoMar Of Scotland In R&D Tie
This article was originally published in PharmAsia News
Executive Summary
China's AsiaPharm and GlycoMar, a biotech based in Scotland, have signed an agreement to conduct research and development for drugs based on marine glycomolecules. The agreement was reached as AsiaPharm, based in Shanghai, faces a takeover bid by MBK Partners, a Korean private-equity firm. Under the agreement with GlycoMar, the Scottish firm is to supply purified marine glycans to AsiaPharm to be studied for possible drug applications. The companies would collaborate on any candidates that result. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.